{
  "figure_1": "Flowchart of the study design.",
  "figure_2": "Molecular clusters of LMF-related genes in HR+ breast cancer. (A) Consensus matrix of unsupervised clustering analysis. (B) Principal Component Analysis (PCA) plots showing distinct separation between the two identified molecular clusters. (C) Kaplan-Meier survival curves comparing overall survival (OS) between the two molecular clusters. (D) Heatmap illustrating gene expression profiles and clinicopathological characteristics across the two molecular clusters. ***P < 0.001.",
  "figure_3": "Biological functional analysis of LMF-related molecular clusters in HR+ breast cancer. (A) Analysis of stromal score, immune score, and ESTIMATE score between the two clusters using the ESTIMATE algorithm. The comparison indicates differences in the tumor microenvironment (TME) composition. (B-D) Differential expression analysis of immune checkpoint molecules PD-1, PD-L1, and CTLA4 between the two molecular clusters. The variation in expression suggests potential differences in immune evasion mechanisms and responses to immunotherapy. (E) Immune cell infiltration analysis comparing the two molecular clusters based on multiple algorithms, providing a comprehensive overview of immune cell infiltration patterns. (F) Hematoxylin and eosin (H&E) staining comparison across different molecular clusters, indicating more lymphocytic infiltration in cluster 2. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.",
  "figure_4": "Construction and validation of the LMF_index and comparison with existing indices. (A) LMF_index panel genes and their corresponding regression coefficients identified by multivariate Cox regression analysis. (B) Distribution of LMF_index and scatter plot of survival status. (C) Sankey diagram depicting the relationships among molecular clusters, LMF_index, and survival status, providing a visual overview of patient classification and outcomes. (D-I) Kaplan-Meier survival curves for the TCGA training cohort, internal validation cohorts and external validation cohorts. (J-N) Time-dependent receiver operating characteristic (ROC) curve analysis comparing the area under the curve (AUC) values at 2, 5, and 8 years for the LMF_index and existing indices. (O) Comparison of the concordance index (C-index) across different indices, demonstrating the overall predictive performance of each index in terms of concordance with actual outcomes.",
  "figure_5": "Independent prognostic analysis of the LMF_index and nomogram construction. (A-B) Univariate and multivariate Cox regression analyses of clinical-pathological characteristics and LMF_index. (C) Construction of a nomogram incorporating LMF_index and clinical-pathological factors. (D) Calibration curves for assessing the accuracy of the nomogram in predicting outcomes. (E-G) Receiver operating characteristic (ROC) curve analysis of the nomogram, risk score, and clinical-pathological factors for predicting 2-year, 5-year, and 8-year survival.",
  "figure_6": "Validation of the prognostic value of LMF_index in the Shanghai cohort. (A) Kaplan-Meier survival analysis comparing the LMF_index low and high groups, using the optimal cut-off value. (B) Time-dependent receiver operating characteristic (ROC) curves of LMF_index at 6, 7, and 8 years in the Shanghai cohort. (C-D) Univariate and multivariate Cox regression analyses of LMF_index combined with clinical and pathological factors in the Shanghai cohort.",
  "figure_7": "Prognostic value of LMF_index in breast cancer tissue microarray. (A) Representative images of KRT5, UGT2B4, BIRC3, MRC1, CD209, FABP7, and KLRB1 based on multiplex immunohistochemistry (mIHC) staining in the LMF_index low group. (B) Representative images of KRT5, UGT2B4, BIRC3, MRC1, CD209, FABP7, and KLRB1 based on mIHC staining in the LMF_index high group. (C) Kaplan-Meier overall survival (OS) analysis comparing the LMF_index low and high groups, using the optimal cut-off value. (D) Time-dependent receiver operating characteristic (ROC) curves of the LMF_index for 2-, 5-, and 8-year OS. (E) Circos plot illustrating the distribution of different clinical factors between the LMF_index low and high groups.",
  "figure_8": "Single-cell transcriptomic expression levels analysis of LMF_index panel genes. (A) Dimensionality reduction and clustering of breast cancer tissue using the Uniform Manifold Approximation and Projection (UMAP) method from the TISCH2 database. (B) Annotation of 28 clusters into 9 different cell types. (C) Dot plot showing the expression levels of marker genes in each cell type. (D-J) Analysis of the expression levels of LMF_index panel genes (KRT5, UGT2B4, BIRC3, MRC1, CD209, FABP7, and KLRB1) at the single-cell level in various immune and tumor cell types.",
  "figure_9": "Immune cell infiltration and immunotherapy sensitivity analysis in different LMF_index groups. (A) Representative multiplex immunohistochemistry (mIHC) images showing CD8, CD68, CD163, and PD-L1 expression in LMF_index low and high groups. (B-F) Quantification of immune cell infiltration, comparing CD8+ T cells, CD68+ (M0-like) macrophages, CD68+CD163- (M1-like) macrophages, CD68+CD163+ (M2-like) macrophages, and PD-L1+ cells between LMF_index low and high groups. (G-J) Comparison of immunophenoscore (IPS) between LMF_index low and high groups. (K) Comparison of pathological complete response (pCR) rates between LMF_index low and high patients who received neoadjuvant immunotherapy in the GSE173839 dataset. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.",
  "figure_10": "KLRB1 expression and immune cell infiltration analysis in breast cancer tissue microarray. (A) Representative multiplex immunohistochemistry (mIHC) images showing PanCK, CD8, KLRB1, PD-L1, CD68, and CD163 expression in the KLRB1 high group. (B-F) Kaplan-Meier overall survival (OS) analysis comparing the infiltration levels of KLRB1+ cells, CD8+ T cells, CD68+ (M0-like) macrophages, CD68+CD163- (M1-like) macrophages, and CD68+CD163+ (M2-like) macrophages. (G) Correlation heatmap analysis of the percentages of KLRB1+ cells, CD8+ T cells, CD68+ (M0-like) macrophages, CD68+CD163- (M1-like) macrophages, and CD68+CD163+ (M2-like) macrophages, and PD-L1+ cells. (H-K) Infiltration level differences in CD8+ T cells, CD68+ (M0-like) macrophages, CD68+CD163- (M1-like) macrophages, and CD68+CD163+ (M2-like) macrophages between KLRB1+ cells high and low breast cancer patients. (L) Differential analysis of KLRB1+ cells between stromal and epithelial regions. (M-O) Kaplan-Meier overall survival analysis based on KLRB1 expression levels in patients receiving PD-1 inhibitors, PD-L1 inhibitors, and CTLA4 inhibitors."
}